GSK2248761 200 mg once daily

DRUG2 trials

Sponsors

ViiV Healthcare

Conditions

Infection, Human Immunodeficiency Virus

Phase 2

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

TerminatedNCT01199731

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2010-10-05End: 2011-07-19Updated: 2017-11-17

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)

TerminatedNCT01231555

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2010-11-18End: 2011-07-04Updated: 2017-11-17